Onkologie. 2007:1(1):28-31

Lung cancer in elderly

Mária Wagnerová
Klinika rádioterapie a onkológie VOÚ, a.s., Koąice

Lung cancer is the leading cause of cancer deaths in Europe and USA. The median age of diagnosis is currently 69 years, however this is gradually increasing with the aging population. Patients over age of 70 represent 40 % of all patients with non-small cell lung cancer. Age alone has not been found to be a significant prognostic factor in many malignancies, including lung cancer with performance status and stage being of greater importance. In lung cancer it is also evident that older patients gain equivalent benefit from cancer therapies as their younger counterparts. Elderly patients are under-treated in all aspects of their disease course from histological diagnosis to active therapy with surgical resection, radiotherapy or chemotherapy, irrespective of performance status or co-morbidities. Elderly patients are also underrepresented in lung cancer clinical trials. In this review is presented knowledge’s about lung cancer in elderly.

Keywords: Key words: lung cancer, elderly, treatment. Key words MeSH: lung neoplasms – drug therapy, surgery, aged; lung neoplasms – radiotherapy, aged.

Published: May 5, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wagnerová M. Lung cancer in elderly. Onkologie. 2007;1(1):28-31.
Download citation

References

  1. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991, 9: 1618-1626. Go to original source... Go to PubMed...
  2. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997, 15: 2996-3018.
  3. Balducci L. New paradigms for treating elderly patients with cancer: the Comprehensive Geriatric Assessment and guidelines for supportive care. J Support Oncol 2003, 1 (suppl 2): p. 30-37. Go to PubMed...
  4. Balducci L. Geriatric oncology: Challenges for the new century. Eur J Cancer 2000, 36: 1741-1754. Go to original source... Go to PubMed...
  5. Beretta GD, Michetti G, Belometti MO, et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 2000, 83: 573-576. Go to original source... Go to PubMed...
  6. Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced nonsmall-cell lung cancer (NSCLC). Br J Cancer 2004, 90: 82-86. Go to original source... Go to PubMed...
  7. Chen YM, Perng RP, Chen MC, et al. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 2003, 40: 221-226. Go to original source... Go to PubMed...
  8. Cohen MH, Williams GA, Sridhara R, et al. FDA approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8: 303-306. Go to original source... Go to PubMed...
  9. Colleoni M, Galon F, Nelli P, et al. Weekly vinorelbine in elderly patients with non-small-cell lung cancer. Tumori 1994, 80: 448-452. Go to original source...
  10. Copin M, Kommareddy A, Behnken D, et al. Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003, 22: 758 (abstr. 3048).
  11. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002, 20: 1786-1792. Go to original source... Go to PubMed...
  12. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000, 117: 1239-1246. Go to original source... Go to PubMed...
  13. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91: 66-72. Go to original source... Go to PubMed...
  14. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2001, 12: 1049-1050. Go to original source... Go to PubMed...
  15. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000, 14: 63-77. Go to original source... Go to PubMed...
  16. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453-471. Go to original source... Go to PubMed...
  17. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: Why so badly treated? Lancet 1990, 335: 1020-1022. Go to original source... Go to PubMed...
  18. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001, 7: 3942-3949.
  19. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel. Ann Oncol 2004, 15: 419-426. Go to original source... Go to PubMed...
  20. Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine vinorelbine in advanced non-smallcell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001, 31: 277-284. Go to original source... Go to PubMed...
  21. Gridelli C, Maione P, Barletta E. Individualized chemotherapy for elderly patients with nonsmall cell lung cancer. Curr Opin Oncol 2002, 14: 199-203. Go to original source... Go to PubMed...
  22. Gridelli C, Manegold C, Mali P, et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: A multicentre phase II trial. Eur J Cancer 2004, 40: 2424-2431. Go to original source... Go to PubMed...
  23. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced nonsmall-cell lung cancer: The Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95: 362-372. Go to original source... Go to PubMed...
  24. Gridelli C, Perrone F, Monfardini S: Lung cancer in the elderly. Eur J Cancer 33:2313-2314, 1997. Go to original source... Go to PubMed...
  25. Hainsworth JD, Burris HA, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer 2000, 89: 328-333. Go to original source...
  26. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003, 98: 779-788. Go to original source... Go to PubMed...
  27. Johnson BE, Lucca J, Rabin MS, et al. A phase II trial of erlotinib in previously untreated elderly patients (70 years) with advanced NSCLC: Preliminary results. Ann Oncol 2004, 15: 169 (suppl 3; abstr 639 PD). Go to PubMed...
  28. Kelly K, Giarritta S, Akerley W, et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001, 20: 329a (abstr 1313).
  29. Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 2000; 7: 548-556. Go to original source... Go to PubMed...
  30. Lilenbaum RC, Herndon J, List M, et al. Single-agent (SA) vs combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Oncol 2002, 21: 1a (abstr 2).
  31. Maestu IC, Gómez-Aldaraví L, Torregrossa MD, et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 2003, 42: 345-354. Go to original source... Go to PubMed...
  32. Molinier O, Milleron B, Breton JL, et al. Multicenter phase II trial of carboplatin and weekly paclitaxel as first-line treatment in elderly patients with non small cell lung cancer: Preliminary results. Proc Am Soc Clin Oncol 2003, 22: 693 (abstr 2786). Go to original source...
  33. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996, 77: 395-401. Go to original source... Go to PubMed...
  34. Nguyen B, Sandler A, Denham C. The safety and efficacy of gemcitabine plus cisplatin in the elderly chemo-naive NSCLC patients (age >= 70 years) as compared to those with age < 70 years. Proc Am Soc Clin Oncol 1999, 18: 471a (abstr 1818). Go to original source...
  35. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311: 899-909. Go to original source...
  36. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2: 533-543. Go to original source... Go to PubMed...
  37. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 20: 494-502. Go to original source... Go to PubMed...
  38. Repetto L, Venturino A, Fratino L, et al. Geriatric oncology: A clinical approach to the older patient with cancer. Eur J Cancer 2003, 39: 870-880. Go to original source... Go to PubMed...
  39. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003, 1 (suppl 2): 18-24. Go to PubMed...
  40. Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicentre phase II study. Lung Cancer 2000, 27: 75-80. Go to original source... Go to PubMed...
  41. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975 - 2000. Bethesda, MD, National Cancer Institute, 2003. http://seer.cancer.gov/csr/1975_2000.
  42. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 22: 622S (abstr 7022).
  43. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: Descriptive study based on scripted interviews. BMJ 1998, 317: 771-775. Go to original source... Go to PubMed...
  44. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: Comparing view of patients with cancer with those of doctors, nurses and general public. BMJ 1990, 300: 1458-1460. Go to original source... Go to PubMed...
  45. Stahel R, Rossi A, Petruzelka L, et al. Lessons from the "Iressa" Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer 2003, 89: S19-S23 (suppl 2). Go to original source... Go to PubMed...
  46. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65: 25-32.
  47. Wingo PA, Cardinez CJ, Landis SH, et al. Long term trends in cancer mortality in the United States. Cancer 2003, 97: 3133-3275 (suppl 12). Go to original source... Go to PubMed...
  48. Zachariah B, Balducci L, Venkattaramanabalaji GV, et al. Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 1997, 39: 1125-1129. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.